全球注射用抗糖尿病藥物市場：現況分析與預測（2023-2030）

Injectables Antidiabetic Drugs Market: Current Analysis and Forecast (2023-2030)

出版日期: 2024年04月01日 | 出版商:

UnivDatos Market Insights Pvt Ltd | 英文 134 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

2023 年至 2030 年，全球注射型抗糖尿病藥物市場預計將以約 6.1% 的複合年增長率成長。注射用抗糖尿病藥物市場是指專注於注射治療糖尿病藥物的製藥產業部分。這些藥物旨在透過增加胰島素分泌、提高胰島素敏感性或減少肝臟中葡萄糖的產生來幫助糖尿病患者調節血糖水平。由於久坐的生活方式、不健康的飲食和人口老化等因素，全球糖尿病盛行率不斷上升，這是市場的主要驅動力。例如，根據世界衛生組織 (WHO) 的統計，全球約有 4.22 億人患有糖尿病。大多數糖尿病患者生活在低收入和中等收入國家。藥物傳遞技術的進步也帶動了更方便、更有效的注射型抗糖尿病藥物的開發。此外，肥胖是第二型糖尿病的主要危險因素，全球肥胖流行與糖尿病盛行率的增加相對應。隨著對抗肥胖的鬥爭取得進展，用於糖尿病管理的注射抗糖尿病藥物的使用也可能會增加。

依藥物類型，市場分為胰島素、胰澱素類似物和 GLP-1 激動劑。其中，胰島素製劑預計將擁有較高的市場佔有率，原因如下。全球第 1 型和第 2 型糖尿病盛行率持續上升，推動了對胰島素產品的需求。隨著越來越多的人被診斷出患有糖尿病，對胰島素治療以實現血糖控制和預防併發症的需求不斷增加。先進的胰島素輸送設備（例如胰島素筆）的出現正在提高給藥的便利性和胰島素治療的依從性。此外，隨著第 2 型糖尿病的進展，許多患者最終可能需要胰島素治療才能達到血糖目標。

根據分銷管道，市場分為醫院藥房、零售藥房和網路藥房。特別是，預計在預測期內，醫院藥局類別注射抗糖尿病藥物的採用率將很高。醫療保健變得越來越複雜，越來越多的患者需要專門護理，包括糖尿病等慢性病患者。醫院藥局在提供藥品和製藥服務以支持醫院內病患照護方面發揮著重要作用。醫療技術的進步促使了包括糖尿病在內的各種疾病的新療法和治療方法的發展。醫院藥局具備儲存、準備和分發這些專用藥物的能力，有助於分銷通路領域的成長。

為了更瞭解注射抗糖尿病藥物產業的市場介紹，將市場分為北美（美國、加拿大和北美其他地區）、歐洲（德國、英國、法國、西班牙、義大利和歐洲其他地區）和亞太地區（中國、日本、印度、亞太地區其他地區），並根據其在世界其他地區的全球影響力進行分析。由於糖尿病盛行率不斷上升、一般人群對注射抗糖尿病藥物的認識不斷提高以及生活方式的改變，北美注射型抗糖尿病藥物市場預計將繼續增長。例如，根據 CDC 的數據，2020 年，65 歲及以上的成年人中有 2,720 萬人患有糖尿病前期，佔該年齡層的 48.8%。預計 2022 年確診糖尿病的總費用為 4,130 億美元，其中直接醫療費用為 3,070 億美元，糖尿病帶來的間接費用為 1,060 億美元。

市場上的主要參與者包括AstraZeneca、 Novartis AG、Johnson & Johnson、Merck & Co. Inc、 Pfizer、Sanofi、Eli lilly、Bristol-Myers Squibb、Oramed、Astellas Pharma Inc.。

The Injectables antidiabetic drugs market is expected to register a CAGR of approx. 6.1% over the period of 2023-2030. The injectable antidiabetic drug market refers to the segment of the pharmaceutical industry focused on medications administered via injection for the treatment of diabetes mellitus. These drugs are designed to help regulate blood sugar levels in individuals with diabetes by either increasing insulin production, improving insulin sensitivity, or reducing glucose production in the liver. The rising prevalence of diabetes worldwide, fueled by factors such as sedentary lifestyles, unhealthy diets, and aging populations, is a significant driver of the market. For instance, According to the World Health Organization (WHO), Approximately 422 million people across the globe have diabetes. The majority of individuals with diabetes reside in low- and middle-income countries. Moreover, Advances in drug delivery technologies have led to the development of more convenient and effective injectable antidiabetic drugs. Furthermore, obesity is a major risk factor for type 2 diabetes, and the global obesity epidemic has led to a corresponding increase in diabetes prevalence. As efforts to address obesity continue, there may be an associated increase in the use of injectable antidiabetic drugs to manage diabetes..

Based on the Drug Type, the market has been categorized into insulin, amylin analogs, glp-1 agonists. Among them, the insulin segment is expected to grow at a higher share in the market due to The global prevalence of diabetes, both type 1 and type 2, continues to rise, driving the demand for insulin. As more people are diagnosed with diabetes, there is a growing need for insulin therapy to achieve glycemic control and prevent complications. The availability of advanced insulin delivery devices, such as insulin pens, has enhanced the ease of administration and adherence to insulin therapy. Moreover, With the progression of type 2 diabetes, many patients may eventually require insulin therapy to achieve glycemic targets.

Based on the distribution channel, the market has been categorized into hospital pharmacies, retail pharmacies, online pharmacies. Among them, the hospital pharmacies category is to witness higher adoption of Injectable Antidiabetic Drug during the forecast period. Healthcare is becoming increasingly complex, with a growing number of patients requiring specialized care, including those with chronic conditions such as diabetes. Hospital pharmacies play a crucial role in providing medications and pharmaceutical services to support patient care within the hospital setting. Advances in medical technology have led to the development of new treatments and therapies for various conditions, including diabetes. Hospital pharmacies are equipped to handle the storage, preparation, and dispensing of these specialized medications, contributing to their growth in the distribution channel segment.

For a better understanding of the market adoption of the Injectables antidiabetic drugs industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, and Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. The North America injectable antidiabetic drug market is expected to continue to grow in the coming years, driven by the increasing prevalence of diabetes and growing awareness of injectable antidiabetic drug among the general population, change in lifestyle. For instance, in 2020, according to CDC, Among adults aged 65 years or older, 27.2 million had prediabetes, which corresponds to 48.8% of this age group. the estimated total cost of diagnosed diabetes in 2022 was $413 billion, $307 billion in direct medical costs, $106 billion in indirect costs attributable to diabetes.

Some of the major players operating in the market include AstraZeneca, Novartis AG, Johnson & Johnson, Merck & Co. Inc, Pfizer, Sanofi, Eli lilly, Bristol-Myers Squibb, Oramed, Astellas Pharma Inc.

1MARKET INTRODUCTION

1.1.Market Definitions
1.2.Main Objective
1.3.Stakeholders
1.4.Limitation

2RESEARCH METHODOLOGY OR ASSUMPTION

2.1.Research Process of the Injectables Antidiabetic Drugs Market
2.2.Research Methodology of the Injectables Antidiabetic Drugs Market
2.4.Respondent Profile

3MARKET SYNOPSIS

4EXECUTIVE SUMMARY

5IMPACT OF COVID-19 ON THE INJECTABLES ANTIDIABETIC DRUGS MARKET

6GLOBAL INJECTABLES ANTIDIABETIC DRUGS MARKET REVENUE, 2020-2030F

7MARKET INSIGHTS BY DRUG TYPE

7.1.Insulin
7.2.Amylin analogs
7.3.GLP-1 agonists

8MARKET INSIGHTS BY DISTRIBUTION CHANNEL

8.1.Hospital Pharmacies
8.2.Retail Pharmacies
8.3.Online Pharmacies

9MARKET INSIGHTS BY REGION

9.1NORTH AMERICA INJECTABLES ANTIDIABETIC DRUGS MARKET
- 9.1.1.U.S.
- 9.1.2.Canada
- 9.1.3.Rest of North America
9.2EUROPE INJECTABLES ANTIDIABETIC DRUGS MARKET
- 9.2.1.Germany
- 9.2.2.U.K.
- 9.2.3.France
- 9.2.4.Italy
- 9.2.5.Spain
- 9.2.6.Rest of Europe
9.3ASIA PACIFIC INJECTABLES ANTIDIABETIC DRUGS MARKET
- 9.3.1.China
- 9.3.2.Japan
- 9.3.3.India
- 9.3.4.Rest of Asia-Pacific
9.4REST OF THE WORLD INJECTABLES ANTIDIABETIC DRUGS MARKET